QT Ultrasound Leadership
Dr. Klock is Chief Executive Officer of QT Ultrasound and Managing Director, Manager, and Founder. Prior to QT Ultrasound, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and eight granted patents.
Margaret Donigan leads the QTbreasthealth team as well as serving as the Chief Strategy Officer of QT Ultrasound. Prior to joining QT Ultrasound, she spent more than a decade in middle market private equity, leading strategy development and making principal investments in more than a dozen companies, covering a variety of industries including healthcare. Ms. Donigan served as Executive Vice President of Corporate Development at Paradigm Tax Group, a company for which she led the recapitalization and served on the Board. She received her B.A. from Yale University and earned her M.B.A. in Finance and Operations Management from the Wharton School at the University of Pennsylvania, where she graduated as a Palmer Scholar.
Mr. LoVetri has experience in manufacturing, software, and IT with industry leaders such as GE, Autodesk, Charles Schwab and BioRad Laboratories. He has an MS in Engineering and proven leadership in enterprise management and bringing products to market.
Dr. Natesan is a board-certified radiologist who brings together years of experience in finance and healthcare. Prior to joining QT Ultrasound, Dr. Natesan led multiple mergers, acquisitions, and financing deals in the medical device, biotech, and pharmaceutical industries, as an investment banker in Lehman Brothers’ Healthcare Group. Dr. Natesan has also served as an Assistant Professor of Diagnostic Radiology at the UT-MD Anderson Cancer Center, and has contributed to multiple publications, national presentations, and grant-funded research in imaging economics.
For over three decades Mr. Pirshafiey has developed products and businesses for domestic and multinational firms. Mr. Pirshafiey’s creativity, innovative problem-solving skills, and entrepreneurial mindset have provided professional, technical, and business solutions to many start-ups and mature companies. He has previously founded and managed two companies with the mission to provide sustainable practices to industries such as medical devices, automotive, aerospace, high-tech, consumer products, and robotics (brief client list: Johnson & Johnson, Siemens, Edwards Life Sciences, Autoliv, TRW). Mr. Pirshafiey has 16 inventions filed with the US patent office, holds a Bachelor of Science in Aeronautical Engineering, and an MBA with specialization in Entrepreneurship.
Brian Brothen brings to QT Ultrasound more than two decades of commercial pharmaceutical, diagnostic, and medical device oncology experience including sales, commercial leadership, business development, strategic planning, and key opinion leader development. Prior to joining QT Ultrasound, Mr. Brothen was the Vice President of Sales at Paradigm Dx. During his time at Paradigm Dx, he led the launch of the company's new NGS cancer diagnostic test to help deliver personalized cancer therapy. Mr. Brothen has held numerous oncology sales and sales leadership positions at Agendia, Pharmion (Celgene), Sanofi, and Schering Plough. Mr. Brothen graduated from the University of South Florida with a degree in Business and Communications.